Wolverine Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-29,335
Closed -$2.05M 1676
2020
Q2
$2.05M Sell
29,335
-28,373
-49% -$1.8M 0.02% 386
2020
Q1
$2.62M Sell
57,708
-3,206
-5% -$182K 0.04% 307
2019
Q4
$3.96M Sell
60,914
-59,632
-49% -$3.99M 0.05% 301
2019
Q3
$7.49M Buy
120,546
+97,623
+426% +$6.13M 0.09% 172
2019
Q2
$1.63M Sell
22,923
-27,091
-54% -$2M 0.02% 492
2019
Q1
$3.92M Buy
+50,014
New +$3.79M 0.05% 269
2016
Q3
Sell
-321
Closed -$23K 1290
2016
Q2
$23K Buy
+321
New +$23.8K ﹤0.01% 1090
2015
Q4
Sell
-125
Closed -$15K 1830
2015
Q3
$15K Buy
125
+3
+2% +$182 ﹤0.01% 1514
2015
Q2
$10K Buy
122
+69
+130% +$3.77K ﹤0.01% 1599
2015
Q1
$8K Sell
53
-591
-92% -$22.6K ﹤0.01% 1578
2014
Q4
$117K Buy
644
+492
+324% +$16K ﹤0.01% 1134
2014
Q3
$57K Buy
+152
New +$5.04K ﹤0.01% 1489

Other funds holding LGND

Wolverine Asset Management's LGND Position: Q3 2016 in Review

Wolverine Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2016, closing a stake of 285 shares — an estimated $21K sold.

Wolverine Asset Management first reported a position in LGND in Q2 2016 and held it in 1 quarter. The position peaked at $21K in Q2 2016. 259 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

  • Wolverine Asset Management reported no remaining Ligand Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Wolverine Asset Management sold 285 Ligand Pharmaceuticals shares in Q3 2016, an estimated $21K.
  • Wolverine Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Wolverine Asset Management's Ligand Pharmaceuticals position peaked at $21K in Q2 2016.
  • 259 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on Wolverine Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.